We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

3 hedge funds and large institutions have $14K invested in F-star Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

1.46% less ownership

Funds ownership: 1.47% → 0.02% (-1.5%)

40% less funds holding

Funds holding: 5 → 3 (-2)

99% less capital invested

Capital invested by funds: $1.08M → $14K (-$1.07M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$1.64K

Top Sellers

Rank Fund Capital Flow
1
PCM
Parsons Capital Management
Rhode Island
-$1.06M
2
TRCT
Tower Research Capital (TRC)
New York
-$9.44K
3
UBS Group
UBS Group
Switzerland
-$4K

FSTX Hedge Fund Activity: Q3 2016 in Review

3 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q3 2016, worth a combined $14K — down 99% from $1.08M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of FSTX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Bank of America, adding an estimated $1.64K. The largest seller was Parsons Capital Management, exiting entirely with an estimated $1.06M sold.

  • 3 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q3 2016, down from 5 in Q2 2016.
  • Funds reported $14K of F-star Therapeutics, Inc. Common Stock stock for Q3 2016, down 99% quarter-over-quarter.
  • 0 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q3 2016 and 2 closed out, a net change of -2 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q3 2016 was Bank of America, an estimated $1.64K added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q3 2016 was Parsons Capital Management, an estimated $1.06M sold.

Based on aggregated 13F filings for Q3 2016.